October 7, 2014 | Teva Pharmaceutical Industries announced that it will halt oncology and women’s health R&D as well as 14 pipeline projects identified in its strategic review. According to the company, the decision came as part of Teva’s strategic review in which the company’s current and future capabilities to meet patient needs, the competitive landscape, barriers to entry and profitability and more were addressed. The company reaffirmed its long-term commitment to develop patient-centric solutions and to grow its specialty medicines business with investment in R&D, marketing, business development and innovation. The pipeline projects that will be discounted amount to nearly $150 million in R&D costs in 2015, and according to the company, these funds will be directed at Teva’s other goals.
Facebook comments